ZA201409006B - Diabetes biomarkers - Google Patents

Diabetes biomarkers

Info

Publication number
ZA201409006B
ZA201409006B ZA2014/09006A ZA201409006A ZA201409006B ZA 201409006 B ZA201409006 B ZA 201409006B ZA 2014/09006 A ZA2014/09006 A ZA 2014/09006A ZA 201409006 A ZA201409006 A ZA 201409006A ZA 201409006 B ZA201409006 B ZA 201409006B
Authority
ZA
South Africa
Prior art keywords
diabetes biomarkers
biomarkers
diabetes
Prior art date
Application number
ZA2014/09006A
Other languages
English (en)
Inventor
Tihamer Orban
Original Assignee
Orban Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orban Biotech Llc filed Critical Orban Biotech Llc
Publication of ZA201409006B publication Critical patent/ZA201409006B/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047Cells of the immune system
    • G01N33/505Cells of the immune system involving T-cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56972White blood cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/042Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ecology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ZA2014/09006A 2012-05-24 2014-12-08 Diabetes biomarkers ZA201409006B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261651144P 2012-05-24 2012-05-24
PCT/US2013/042627 WO2013177505A1 (en) 2012-05-24 2013-05-24 Diabetes biomarkers

Publications (1)

Publication Number Publication Date
ZA201409006B true ZA201409006B (en) 2016-07-27

Family

ID=49621783

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2014/09006A ZA201409006B (en) 2012-05-24 2014-12-08 Diabetes biomarkers

Country Status (13)

Country Link
US (5) US20130316375A1 (https=)
EP (2) EP2856149B1 (https=)
JP (5) JP6312332B2 (https=)
KR (1) KR102172285B1 (https=)
CN (1) CN104520707B (https=)
AU (4) AU2013266145A1 (https=)
CA (1) CA2874507A1 (https=)
DK (1) DK2856149T3 (https=)
ES (1) ES2810227T3 (https=)
IN (1) IN2014DN10259A (https=)
MX (1) MX357169B (https=)
WO (1) WO2013177505A1 (https=)
ZA (1) ZA201409006B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
US20130316375A1 (en) * 2012-05-24 2013-11-28 Orban Biotech Llc Diabetes biomarkers
KR20150033703A (ko) 2012-06-27 2015-04-01 오르반 바이오테크 엘엘씨 당뇨병 치료를 위한 ctla4 융합 단백질
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
WO2016103390A1 (ja) * 2014-12-25 2016-06-30 株式会社日立製作所 インスリン分泌能分析装置、当該装置を備えるインスリン分泌能分析システム及びインスリン分泌能分析方法
CN105567851A (zh) * 2016-02-29 2016-05-11 北京泱深生物信息技术有限公司 一种与糖尿病相关的分子标志物
WO2017162759A1 (en) * 2016-03-22 2017-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits of assessing status, risk or prognosis of type 1 diabetes
WO2021260654A1 (en) 2020-06-26 2021-12-30 Phaim Pharma Ltd Psoriasis and other autoimmune diseases antigen immune modulator (aim) therapeutic platform
US20240277768A1 (en) 2021-06-17 2024-08-22 Tihamer Orban Individualized Cell Therapy Using Patient-Derived Antigen-Specific Regulatory T Cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2007037544A1 (ja) * 2005-09-30 2009-04-16 国立大学法人京都大学 制御性t細胞の製造を向上させる薬剤のスクリーニング方法の開発、及び免疫抑制性のマクロライド系抗生剤を用いる制御性t細胞の製造方法
WO2009120341A2 (en) * 2008-03-24 2009-10-01 University Of South Florida Biomarkers for predicting response to immunosuppressive therapy
US20100080784A1 (en) * 2008-09-12 2010-04-01 Torrey Pines Institute For Molecular Studies Methods for treating cachexia and lymphopenia
US20130316375A1 (en) * 2012-05-24 2013-11-28 Orban Biotech Llc Diabetes biomarkers
JP7618502B2 (ja) * 2021-05-14 2025-01-21 東京計器株式会社 船舶用自動操舵装置

Also Published As

Publication number Publication date
JP6761827B2 (ja) 2020-09-30
EP2856149A4 (en) 2016-06-01
JP2018116061A (ja) 2018-07-26
KR20150022878A (ko) 2015-03-04
MX2014014348A (es) 2015-06-05
AU2019200824A1 (en) 2019-04-04
US20160299128A1 (en) 2016-10-13
AU2023222980A1 (en) 2023-09-21
US20250237643A1 (en) 2025-07-24
JP2021001899A (ja) 2021-01-07
DK2856149T3 (da) 2020-08-17
CA2874507A1 (en) 2013-11-28
US20130316375A1 (en) 2013-11-28
KR102172285B1 (ko) 2020-11-02
JP2024150702A (ja) 2024-10-23
ES2810227T3 (es) 2021-03-08
US20190137483A1 (en) 2019-05-09
EP2856149B1 (en) 2020-07-08
US20230333094A1 (en) 2023-10-19
JP2015520378A (ja) 2015-07-16
IN2014DN10259A (https=) 2015-08-07
AU2021202609A1 (en) 2021-05-27
CN104520707B (zh) 2018-03-27
JP2023011814A (ja) 2023-01-24
CN104520707A (zh) 2015-04-15
AU2013266145A1 (en) 2015-01-15
AU2019200824B2 (en) 2021-06-24
JP6312332B2 (ja) 2018-04-18
WO2013177505A1 (en) 2013-11-28
MX357169B (es) 2018-06-28
EP3767295A1 (en) 2021-01-20
EP2856149A1 (en) 2015-04-08

Similar Documents

Publication Publication Date Title
GB201213567D0 (en) Biomarkers
GB201201727D0 (en) Indicating locations
GB201211982D0 (en) Biomarker
GB2526439B (en) Dual Configuartion computer
ZA201409006B (en) Diabetes biomarkers
GB201021502D0 (en) Biomarkers
GB201008340D0 (en) Biomarkers
GB201018056D0 (en) Biomarkers
GB201104556D0 (en) Biomarkers
GB201210565D0 (en) Biomarkers
GB2504567B (en) Anti-Relatch Mechanism
GB201211158D0 (en) Biomarkers and uses thereof
GB201005561D0 (en) Biomarkers
GB201001444D0 (en) Biomarkers
PL2626134T3 (pl) Pipeta
GB201010316D0 (en) Biomarkers
EP2712550A4 (en) LANCET
GB201117172D0 (en) Diabetes
GB201113968D0 (en) Prognostic methadology
GB201005456D0 (en) Biomarkers
SG11201504853VA (en) Immunoassay
GB201209802D0 (en) Biomarker
GB201202944D0 (en) Biomarker
GB201210587D0 (en) Predictive biomarker
GB201001419D0 (en) Biomarkers